SpyGlass Pharma Revenue and Competitors
Estimated Revenue & Valuation
- SpyGlass Pharma's estimated annual revenue is currently $4.1M per year.
- SpyGlass Pharma's estimated revenue per employee is $100,500
- SpyGlass Pharma's total funding is $124M.
Employee Data
- SpyGlass Pharma has 41 Employees.
- SpyGlass Pharma grew their employee count by 17% last year.
SpyGlass Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and CTO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Co-founder, President and Executive Chair | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | VP CorpDev and Head Strategy | Reveal Email/Phone |
6 | VP, Human Resources | Reveal Email/Phone |
7 | VP, Finance | Reveal Email/Phone |
8 | SVP Regulatory and Quality | Reveal Email/Phone |
9 | VP, Finance | Reveal Email/Phone |
10 | Sr. Director, Drug Development | Reveal Email/Phone |
SpyGlass Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $102.7M | 511 | 25% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $38.6M | 192 | 3% | N/A | N/A |
#4 | $35M | 127 | 2% | $62.5M | N/A |
#5 | $36.6M | 182 | 18% | N/A | N/A |
#6 | $131.9M | 656 | -3% | N/A | N/A |
#7 | $133.5M | 664 | N/A | N/A | N/A |
#8 | $72.8M | 362 | -4% | N/A | N/A |
#9 | $551.9M | 1716 | -2% | N/A | N/A |
#10 | $11.7M | 58 | 12% | N/A | N/A |
What Is SpyGlass Pharma?
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.
keywords:N/A$124M
Total Funding
41
Number of Employees
$4.1M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.9M | 41 | 21% | N/A |
#2 | $9.1M | 42 | 2% | N/A |
#3 | $5.8M | 44 | -8% | N/A |
#4 | $5.1M | 44 | 29% | N/A |
#5 | $3.7M | 46 | -2% | N/A |